<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial
<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial have?
<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial has 9 citations in the OpenAlex counts ScholarIQ stores.
When was <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial published?
<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial has 2024 year in the ScholarIQ index.
What is the open-access status of <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial?
<scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial has closed oa status in the ScholarIQ index.
What is the DOI of <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial?
The DOI for <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial is on the source record.
What is the PMID of <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial?
The PMID for <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial is on the source record.
What is the OpenAlex record for <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial?
The OpenAlex for <scp>SGLT2</scp> inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial is on the source record.